Real-World Geographic Atrophy Growth Before and After Intravitreal Avacincaptad Pegol Treatment: A Retrospective Cohort Study
In a real-world retrospective cohort study of 114 eyes, intravitreal avacincaptad pegol treatment significantly slowed the progression of geographic atrophy by approximately 22–23% over one year without affecting visual acuity decline, with benefits observed across various AMD subtypes and lesion locations.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human eye relies on a delicate layer of tissue at the back, known as the retina, to capture light and send images to the brain. In a condition called age-related macular degeneration, this tissue slowly deteriorates. One of the most severe forms of this disease is geographic atrophy, where patches of the retina simply die off, leaving permanent blind spots in a person's central vision. For decades, once this tissue was lost, it was considered gone forever, with no way to stop the damage from spreading. However, in recent years, new medicines have emerged that target the underlying inflammation driving this cell death. These drugs are designed not to restore sight, but to act as a brake, slowing the rate at which the blind patches grow larger. The question facing doctors and patients is whether these treatments work as well in the messy, unpredictable reality of everyday clinics as they do in the controlled environment of clinical trials.
A team of researchers at Duke University Medical Center set out to answer this question by looking at the real-world results of a specific treatment called avacincaptad pegol. This medicine is injected directly into the eye and works by blocking a part of the immune system that mistakenly attacks healthy retinal cells. The researchers gathered data from 74 patients, representing 114 eyes, who had received this treatment at their center. They compared how fast the blind spots grew in the year before the first injection against how fast they grew in the year after the treatment began. To measure this growth, the team used high-resolution scans of the retina, manually tracing the edges of the damaged areas on the images to calculate the speed of expansion. They focused on two different ways of measuring this growth: one that accounts for the fact that larger spots naturally tend to grow faster in raw area, and another that adjusts for the shape and size of the lesion to give a fairer comparison.
The results showed a clear and significant slowing of the disease. In the year before treatment, the blind spots were expanding at a certain speed. After the injections began, that speed dropped by roughly 23 percent. This means the treatment successfully slowed the progression of the tissue loss in the average patient. The study found that this benefit was consistent across different types of patients. It worked for those with the most common form of the disease, as well as for those who also had a different, fluid-leaking type of macular degeneration. It also worked for patients whose blind spots were located right in the center of their vision, a group that was excluded from the major clinical trials that originally approved the drug. The researchers noted that the patients received an average of seven injections over the study period, which is fewer than the strict monthly schedule used in trials, yet the treatment still showed a strong effect.
Despite the success in slowing the physical damage, the study highlighted a complex reality regarding vision. While the growth of the blind spots slowed down significantly, the patients' ability to see did not improve, nor did the rate of vision loss change. The patients continued to lose visual sharpness at the same pace they were losing it before the treatment started. This finding aligns with what was seen in the original clinical trials and suggests that while the drug can preserve the remaining tissue, it cannot repair the damage that has already occurred or instantly restore the function of the eye. The researchers concluded that the treatment is effective at its primary goal of slowing the spread of geographic atrophy in real-world settings, offering a tangible benefit in preserving the structure of the eye, even if the immediate visual improvement remains elusive.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.